Comparison · NCT01270971-sae
AN2690 Topical Solution, 5% vs Solution Vehicle: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. AN2690 Topical Solution, 5% vs Solution Vehicle: serious adverse events. Trial comparisons, record NCT01270971-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01270971-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0303 | 0.0174 | 0.0522 | wilson | |
| Risk in group 2 | 0.0415 | 0.0212 | 0.0796 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0111 | -0.0515 | 0.0187 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.731 | 0.304 | 1.76 | log | |
| Odds ratio, group 1 over group 2 | 0.723 | 0.29 | 1.8 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on AN2690 Topical Solution, 5% than on Solution Vehicle | 89.7 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: vehicle.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | AN2690 Topical Solution, 5% | AN2690 Topical Solution, 5%~AN2690 Topical Solution, 5%: AN2690 Topical Solution, 5%, applied once daily for 48 weeks | 12 | 396 | EG000 |
| Group 2 | Solution Vehicle | Solution Vehicle~Solution Vehicle: AN2690 Topical Solution, Vehicle, applied once daily for 48 weeks | 8 | 193 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Up to Week 52
Source ClinicalTrials.gov
Trial
- Title
- Efficacy and Safety Evaluation of AN2690 Topical Solution to Treat Onychomycosis of the Toenail
- NCT number
- NCT01270971
- Phases
- PHASE3
- Conditions
- Onychomycosis of Toenails
- Interventions
- AN2690 Topical Solution, 5%, Solution Vehicle
- Lead sponsor
- Pfizer
- Results first posted
- 2014-08-15
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01270971?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01270971-sae